MicroRNA 221/222 cluster kicks out Timp-3 to inflame the liver

Menghini, Rossella; Federici, Massimo

doi:10.1016/j.ebiom.2018.10.040

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the fact that its level changes significantly in the group of patients with NAFLD, the use of miR-16-5p as an internal control needs to be reconsidered in future studies. 14 miRNAs Were Upregulated in the Group of Patients With NASH Analysis of the literature showed that the results of our screening were consistent with other studies: 12 of 14 miRNAs that showed increased expression according to the results of our screening, namely miR-15b, miR-21, miR-23a, miR-26a, miR-155, miR-200c, miR-222, miR-224, miR-374a, miR-423, let-7a and let-7c were upregulated in the serum of patients with NASH in other studies (Cheung et al, 2008;Yamada et al, 2013;Csak et al, 2015;Gerhard and DiStefano, 2015;Pirola et al, 2015;Liu Z. et al, 2016;Dongiovanni et al, 2018;Matsuura et al, 2018;Menghini and Federici, 2018). The levels of miR-23a, miR-224, miR-200, miR-21, miR-423 were increased not only in the serum but also in liver tissue of patients with NASH (Cheung et al, 2008).…”

Section: Discussionsupporting

confidence: 93%

Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis

Vulf

Skuratovskaia

Komar

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is emerging as one of the most common chronic liver diseases worldwide, affecting 25% of the world population. In recent years, there has been increasing evidence for the involvement of microRNAs in the epigenetic regulation of genes taking part in the development of steatosis and steatohepatitis—two main stages of NAFLD pathogenesis. In the present study, miRNA profiles were studied in groups of patients with steatosis and steatohepatitis to compare the characteristics of RNA-dependent epigenetic regulation of the stages of NAFLD development. According to the results of miRNA screening, 23 miRNAs were differentially expressed serum in a group of patients with steatohepatitis and 2 in a group of patients with steatosis. MiR-195-5p and miR-16-5p are common differentially expressed miRNAs for both steatosis and steatohepatitis. We analyzed the obtained results: the search for target genes for the differentially expressed miRNAs in our study and the subsequent gene set enrichment analysis performed on KEGG and REACTOME databases revealed which metabolic pathways undergo changes in RNA-dependent epigenetic regulation in steatosis and steatohepatitis. New findings within the framework of this study are the dysregulation of neurohumoral pathways in the pathogenesis of NAFLD as an object of changes in RNA-dependent epigenetic regulation. The miRNAs differentially expressed in our study were found to target 7% of genes in the classic pathogenesis of NAFLD in the group of patients with steatosis and 50% in the group of patients with steatohepatitis. The effects of these microRNAs on genes for the pathogenesis of NAFLD were analyzed in detail. MiR-374a-5p, miR-1-3p and miR-23a-3p do not target genes directly involved in the pathogenesis of NAFLD. The differentially expressed miRNAs found in this study target genes largely responsible for mitochondrial function. The role of miR-423-5p, miR-143-5p and miR-200c-3 in regulating apoptotic processes in the liver and hepatocarcinogenesis is of interest for future experimental studies. These miR-374a, miR-143, miR-1, miR-23a, and miR-423 have potential for steatohepatitis diagnosis and are poorly studied in the context of NAFLD. Thus, this work opens up prospects for further studies of microRNAs as diagnostic and therapeutic biomarkers for NAFLD.

show abstract

Section: Discussionsupporting

confidence: 93%

Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis

Vulf

Skuratovskaia

Komar

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review

Martino

Arbitrio

Caracciolo

et al. 2022

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma—A Review

Oura

Morishita

Masaki

2020

IJMS

108

View full text Add to dashboard Cite

Liver cancer is the fourth leading cause of cancer deaths globally, of which hepatocellular carcinoma (HCC) is the major subtype. Viral hepatitis B and C infections, alcohol abuse, and metabolic disorders are multiple risk factors for liver cirrhosis and HCC development. Although great therapeutic advances have been made in recent decades, the prognosis for HCC patients remains poor due to late diagnosis, chemotherapy failure, and frequent recurrence. MicroRNAs (miRNAs) are endogenous, non-coding RNAs that regulate various molecular biological phenomena by suppressing the translation of target messenger RNAs (mRNAs). miRNAs, which often become dysregulated in malignancy, control cell proliferation, migration, invasion, and development in HCC by promoting or suppressing tumors. Exploring the detailed mechanisms underlying miRNA-mediated HCC development and progression can likely improve the outcomes of patients with HCC. This review summarizes the molecular and functional roles of miRNAs in the pathogenesis of HCC. Further, it elucidates the utility of miRNAs as novel biomarkers and therapeutic targets.

show abstract

MicroRNA 221/222 cluster kicks out Timp-3 to inflame the liver

Cited by 3 publications

References 10 publications

Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis

Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis

miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review

Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma—A Review

Contact Info

Product

Resources

About